DDIT3 and diffuse large B-cell lymphoma: The phase III PHOENIX study (NCT01855750) evaluated the outcomes of ibrutinib+R‐CHOP versus placebo+R‐CHOP in patients (N = 838) with untreated non‐GCB DLBCL [18].